Vaxxinity
Vaxxinity is a U.S.-based company pioneering synthetic peptide vaccines to treat and prevent chronic and infectious diseases, including Alzheimer's, Parkinson's, and COVID-19.
Company Overview
Vaxxinity is a U.S.-based company dedicated to democratizing health by pioneering the third biologic revolution. The company focuses on developing synthetic peptide vaccines to treat and prevent chronic diseases such as Alzheimer's, Parkinson's, migraine, and hypercholesterolemia, as well as infectious diseases like COVID-19. Utilizing a proprietary technology platform, Vaxxinity aims to provide medicines that are cheaper, safer, more convenient, and effective for all.
Therapeutic Areas
Vaxxinity's broad therapeutic pipeline spans multiple areas including neurodegeneration, chronic diseases, and infectious diseases. Key products include UB-311 targeting aggregated Aβ in the brain for Alzheimer's, UB-312 focusing on aggregated α-synuclein for Parkinson's and other synucleinopathies, VXX-301 for anti-tau addressing multiple neurodegenerative conditions, UB-313 targeting CGRP for migraines, and VXX-401 aiming at PCSK9 to lower LDL cholesterol and reduce cardiac risks.
AIM Platform
Vaxxinity's Advanced Immunotherapy (AIM) platform is designed to harness the immune system, converting the body into a natural 'drug factory' by stimulating the production of antibodies. Utilizing synthetic peptides, the AIM platform replicates and combines biological epitopes to selectively activate the immune system. It has been scientifically validated, with billions of doses commercialized in animal health and multiple human clinical trials completed or ongoing.
Infectious Disease Initiatives
Vaxxinity is actively engaged in combating infectious diseases, including COVID-19. Its candidate UB-612 employs a 'multitope' approach to neutralize the SARS-CoV-2 virus and is undergoing Phase 3 heterologous boost trials. The company is committed to the rapid development and deployment of immunotherapeutic vaccines, aiming to provide next-generation products efficiently.
Frontier Exploration Laboratory
Based on the Space Coast of Florida, Vaxxinity's Frontier Exploration Laboratory is a hub for innovation. The facility's logo, designed by Michael Okuda—renowned for his work on Star Trek—symbolizes the company's forward-thinking approach and commitment to exploring new frontiers in vaccine technology and chronic disease treatment.